Reduced dose capecitabine is an effective and well-tolerated treatment in patients with metastatic breast cancer
- 31 October 2005
- journal article
- Published by Elsevier BV in The Breast
- Vol. 14 (5), 368-374
- https://doi.org/10.1016/j.breast.2004.12.005
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Multicenter phase II study of oral capecitabine (Xeloda“) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapyAnnals of Oncology, 2003
- Monotherapy options in the management of metastatic breast cancerSeminars in Oncology, 2003
- Multicenter, Phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patientsCancer, 2001
- Capecitabine, an Oral Fluoropyrimidine Carbamate With Substantial Activity in Advanced Colorectal Cancer: Results of a Randomized Phase II StudyJournal of Clinical Oncology, 2000
- Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patientsCancer Chemotherapy and Pharmacology, 2000
- Multicenter Phase II Study of Capecitabine in Paclitaxel-Refractory Metastatic Breast CancerJournal of Clinical Oncology, 1999
- Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissueEuropean Journal of Cancer, 1998
- Dose-intensive vinorelbine with concurrent granulocyte colony-stimulating factor support in paclitaxel-refractory metastatic breast cancer.Journal of Clinical Oncology, 1997
- Patient preferences for oral versus intravenous palliative chemotherapy.Journal of Clinical Oncology, 1997
- Vinorelbine-induced neurotoxicity in patients with advanced breast cancer pretreated with paclitaxel - a phase II studyCancer Chemotherapy and Pharmacology, 1996